Broad-Spectrum Anti-Cancer
Avatrombopag (Everest)
Original price was: £208.00.£182.00Current price is: £182.00.Avatrombopag (Avatrombopag) is an oral thrombopoietin receptor agonist (TPO-RA) designed to stimulate bone marrow platelet production and help reduce the risk of bleeding caused by thrombocytopenia.
MedFind provides overseas sourcing services for Avatrombopag through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Supports platelet recovery for patients with low platelet counts before surgery and those with chronic immune thrombocytopenia (ITP), with product authenticity assurance, fast shipment availability, and professional consultation support.
Larotrectinib / Vitrakvi (Everest)
Price range: £269.00 through £554.00Larotrectinib (Brand name: Vitrakvi) manufactured by Everest Pharma is a targeted therapy used for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring NTRK gene fusions, regardless of where the cancer originated in the body.
Larotrectinib became the first FDA-approved tumor-agnostic targeted therapy based solely on the presence of a specific genetic mutation rather than cancer type or tumor location.
Clinical studies demonstrated efficacy across 17 different adult and pediatric tumor types, highlighting its broad-spectrum anticancer activity in patients with NTRK fusion-positive cancers.